US clinical-stage biotech developing microRNA-targeted therapies for oncology, with a lead candidate for acute myeloid leukaemia.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Acquired by Thalia Therapeutics Thalia Therapeutics acquired US biotech Sanmirna Therapeutics for an initial consideration plus deferred milestone payments, bringing its clinical-stage AML microRNA candidate miRisten into Thalia's pipeline. | $4.8M |
Data is community-curated and may be incomplete.